Home
/
Tempest Therapeutics, Inc.
/
Financials
/
Quarterly
Tempest Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Tempest Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$67.0K
May 3, 2018
Q3
2017
Sep 30, 2017
$56.0K
Nov 2, 2017
Q2
2017
Jun 30, 2017
$84.0K
Aug 3, 2017
Q1
2018
Mar 31, 2017
$63.0K
May 3, 2018
Q3
2017
Sep 30, 2016
$197.0K
Nov 2, 2017
Q2
2017
Jun 30, 2016
$189.0K
Aug 3, 2017
Q1
2017
Mar 31, 2016
$146.0K
May 9, 2017
Q3
2016
Sep 30, 2015
$75.0K
Nov 3, 2016
Q2
2016
Jun 30, 2015
$30.0K
Aug 4, 2016
Q1
2016
Mar 31, 2015
$15.0K
May 5, 2016
Q3
2015
Sep 30, 2014
$0
Nov 5, 2015
Q2
2015
Jun 30, 2014
$0
Aug 10, 2015
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Sep 30, 2018
$55.0K
Nov 9, 2018
Q2
2018
Jun 30, 2018
$81.0K
Aug 9, 2018
Q3
2018
Sep 30, 2017
$56.0K
Nov 9, 2018
Q2
2018
Jun 30, 2017
$84.0K
Aug 9, 2018
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.51M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($7.87M)
Aug 11, 2025
Q3
2025
Jun 30, 2025
($7.87M)
Nov 5, 2025
Q1
2025
Mar 31, 2025
($10.86M)
May 13, 2025
Q2
2025
Mar 31, 2025
($10.86M)
Aug 11, 2025
Q3
2025
Mar 31, 2025
($10.86M)
Nov 5, 2025
Q3
2025
Sep 30, 2024
($10.56M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($9.57M)
Aug 11, 2025
Q3
2025
Jun 30, 2024
($9.57M)
Nov 5, 2025
Q1
2025
Mar 31, 2024
($7.90M)
May 13, 2025
Q2
2025
Mar 31, 2024
($7.90M)
Aug 11, 2025
Q3
2025
Mar 31, 2024
($7.90M)
Nov 5, 2025
Q3
2024
Sep 30, 2023
($6.79M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($7.58M)
Aug 8, 2024
Q3
2024
Jun 30, 2023
($7.58M)
Nov 12, 2024
Q1
2024
Mar 31, 2023
($7.64M)
May 9, 2024
Q2
2024
Mar 31, 2023
($7.64M)
Aug 8, 2024
Q3
2024
Mar 31, 2023
($7.64M)
Nov 12, 2024
Q3
2023
Sep 30, 2022
($8.95M)
Nov 8, 2023
Q3
2023
Jun 30, 2022
($9.17M)
Nov 8, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.60M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($7.97M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($10.94M)
May 13, 2025
Q3
2025
Sep 30, 2024
($10.55M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($9.58M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($7.97M)
May 13, 2025
Q3
2024
Sep 30, 2023
($6.59M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($7.47M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($7.58M)
May 9, 2024
Q3
2023
Sep 30, 2022
($8.77M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($8.77M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($8.16M)
May 10, 2023
Q3
2022
Sep 30, 2021
($7.74M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($6.79M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($5.13M)
May 13, 2022
Q3
2021
Sep 30, 2020
$5.43M
Nov 10, 2021
Q2
2021
Jun 30, 2020
($5.24M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($12.14M)
May 13, 2021
Q3
2020
Sep 30, 2019
($11.75M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($10.16M)
Aug 10, 2020